<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339909</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1433</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091433</ELocationID><Abstract><AbstractText>MoMo30 is an antiviral protein isolated from aqueous extracts of <i>Momordica balsamina</i> L. (Senegalese bitter melon). Previously, we demonstrated MoMo30's antiviral activity against HIV-1. Here, we explore whether MoMo30 has antiviral activity against the COVID-19 virus, SARS-CoV-2. MLV particles pseudotyped with the SARS-CoV-2 Spike glycoprotein and a Luciferase reporter gene (SARS2-PsV) were developed from a three-way co-transfection of HEK293-T17 cells. MoMo30's inhibition of SARS2-PsV infection was measured using a luciferase assay and its cytotoxicity using an XTT assay. Additionally, MoMo30's interactions with the variants and domains of Spike were determined by ELISA. We show that MoMo30 inhibits SARS2-PsV infection. We also report evidence of the direct interaction of MoMo30 and SARS-CoV-2 Spike from WH-1, Alpha, Delta, and Omicron variants. Furthermore, MoMo30 interacts with both the S1 and S2 domains of Spike but not the receptor binding domain (RBD), suggesting that MoMo30 inhibits SARS-CoV-2 infection by inhibiting fusion of the virus and the host cell via interactions with Spike.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeBarros</LastName><ForeName>Kenya</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1644-547X</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Mahfuz</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8964-3381</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bond</LastName><ForeName>Vincent C</ForeName><Initials>VC</Initials><Identifier Source="ORCID">0000-0002-3999-3076</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Floyd</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Community Health and Preventive Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gbodossou</LastName><ForeName>Erick</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>PROMETRA International, Dakar-Etoile BP 6134, Senegal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Amad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Malango Traditional Healers Association, Fatick BP 1763, Senegal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumpe</LastName><ForeName>Lauren R H</ForeName><Initials>LRH</Initials><AffiliationInfo><Affiliation>Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>Barry R</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0003-0772-4856</Identifier><AffiliationInfo><Affiliation>Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Natural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0001-7698-4841</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="Y">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000089942" MajorTopicYN="N">Viral Pseudotyping</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MoMo30</Keyword><Keyword MajorTopicYN="N">Pseudovirus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">antiviral plant</Keyword><Keyword MajorTopicYN="N">antiviral protein</Keyword><Keyword MajorTopicYN="N">ethnopharmacology</Keyword><Keyword MajorTopicYN="N">extract</Keyword><Keyword MajorTopicYN="N">fusion inhibitor</Keyword><Keyword MajorTopicYN="N">traditional medicine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339909</ArticleId><ArticleId IdType="pmc">PMC11437407</ArticleId><ArticleId IdType="doi">10.3390/v16091433</ArticleId><ArticleId IdType="pii">v16091433</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor D.M., Werneke U. Ethnopharmacology(dagger) Nord. J. Psychiatry. 2018;72:S30–S32. doi: 10.1080/08039488.2018.1525636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08039488.2018.1525636</ArticleId><ArticleId IdType="pubmed">30688173</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontanarosa P.B., Lundberg G.D. Alternative medicine meets science. JAMA. 1998;280:1618–1619. doi: 10.1001/jama.280.18.1618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.280.18.1618</ArticleId><ArticleId IdType="pubmed">9820267</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang E.F., Ng T.B. Bitter gourd (Momordica charantia) is a cornucopia of health: A review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr. Mol. Med. 2011;11:417–436. doi: 10.2174/156652411795976583.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795976583</ArticleId><ArticleId IdType="pubmed">21568930</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover J.K., Yadav S.P. Pharmacological actions and potential uses of Momordica charantia: A review. J. Ethnopharmacol. 2004;93:123–132. doi: 10.1016/j.jep.2004.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2004.03.035</ArticleId><ArticleId IdType="pubmed">15182917</ArticleId></ArticleIdList></Reference><Reference><Citation>Beloin N., Gbeassor M., Akpagana K., Hudson J., de Soussa K., Koumaglo K., Arnason J.T. Ethnomedicinal uses of Momordicacharantia (Cucurbitaceae) in Togo and relation to its phytochemistry and biological activity. J. Ethnopharmacol. 2005;96:49–55. doi: 10.1016/j.jep.2004.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2004.08.009</ArticleId><ArticleId IdType="pubmed">15588650</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter E., Geetha T., Burnett D., Broderick T.L., Babu J.R. The Effects of Momordica charantia on Type 2 Diabetes Mellitus and Alzheimer’s Disease. Int. J. Mol. Sci. 2023;24:4643. doi: 10.3390/ijms24054643.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24054643</ArticleId><ArticleId IdType="pmc">PMC10002567</ArticleId><ArticleId IdType="pubmed">36902074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee-Huang S., Huang P.L., Chen H.C., Huang P.L. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene. 1995;161:151–156. doi: 10.1016/0378-1119(95)00186-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1119(95)00186-A</ArticleId><ArticleId IdType="pubmed">7665070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourinbaiar A.S., Lee-Huang S. Potentiation of anti-HIV activity of anti-inflammatory drugs, dexamethasone and indomethacin, by MAP30, the antiviral agent from bitter melon. Biochem. Biophys. Res. Commun. 1995;208:779–785. doi: 10.1006/bbrc.1995.1405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1995.1405</ArticleId><ArticleId IdType="pubmed">7695636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiratchariyakul W., Wiwat C., Vongsakul M., Somanabandhu A., Leelamanit W., Fujii I., Suwannaroj N., Ebizuka Y. HIV inhibitor from Thai bitter gourd. Planta Med. 2001;67:350–353. doi: 10.1055/s-2001-14323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2001-14323</ArticleId><ArticleId IdType="pubmed">11458453</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman M.I., Khan M., Gbodossou E., Diop A., DeBarros K., Duong H., Bond V.C., Floyd V., Kondwani K., Montgomery Rice V., et al. Identification of a Novel Anti-HIV-1 Protein from Momordica balsamina Leaf Extract. Int. J. Environ. Res. Public Health. 2022;19:15227. doi: 10.3390/ijerph192215227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192215227</ArticleId><ArticleId IdType="pmc">PMC9690441</ArticleId><ArticleId IdType="pubmed">36429944</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M., Diop A., Gbodossou E., Xiao P., Coleman M., De Barros K., Duong H., Bond V.C., Floyd V., Kondwani K., et al. Anti-human immunodeficiency virus-1 activity of MoMo30 protein isolated from the traditional African medicinal plant Momordica balsamina. Virol. J. 2023;20:50. doi: 10.1186/s12985-023-02010-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02010-5</ArticleId><ArticleId IdType="pmc">PMC10035133</ArticleId><ArticleId IdType="pubmed">36949470</ArticleId></ArticleIdList></Reference><Reference><Citation>PROMETRA.  [(accessed on 2 July 2024)].  Available online:  https://prometra.org/</Citation></Reference><Reference><Citation>Citores L., Iglesias R., Ferreras J.M. Antiviral Activity of Ribosome-Inactivating Proteins. Toxins. 2021;13:80. doi: 10.3390/toxins13020080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins13020080</ArticleId><ArticleId IdType="pmc">PMC7912582</ArticleId><ArticleId IdType="pubmed">33499086</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond M.S., Kanneganti T.D. Innate immunity: The first line of defense against SARS-CoV-2. Nat. Immunol. 2022;23:165–176. doi: 10.1038/s41590-021-01091-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Cases WHO COVID-19 Dashboard. 2024.  [(accessed on 1 September 2024)].  Available online:  https://data.who.int/dashboards/covid19/caseshttps://data.who.int/dashboards/covid19/deaths.</Citation></Reference><Reference><Citation>Jogalekar M.P., Veerabathini A., Gangadaran P. Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions. Exp. Biol. Med. 2020;245:964–969. doi: 10.1177/1535370220920540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370220920540</ArticleId><ArticleId IdType="pmc">PMC7327953</ArticleId><ArticleId IdType="pubmed">32306751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Pohlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol. Cell. 2020;78:779–784 e5. doi: 10.1016/j.molcel.2020.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.04.022</ArticleId><ArticleId IdType="pmc">PMC7194065</ArticleId><ArticleId IdType="pubmed">32362314</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal M., Berhanu G., Desalegn C., Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020;12:e7423. doi: 10.7759/cureus.7423.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.7423</ArticleId><ArticleId IdType="pmc">PMC7182166</ArticleId><ArticleId IdType="pubmed">32337143</ArticleId></ArticleIdList></Reference><Reference><Citation>Magagnoli J., Narendran S., Pereira F., Cummings T.H., Hardin J.W., Sutton S.S., Ambati J. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. medRxiv. 2020 doi: 10.1016/j.medj.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7274588</ArticleId><ArticleId IdType="pubmed">32838355</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcolino M.S., Meira K.C., Guimarães N.S., Motta P.P., Chagas V.S., Kelles S.M.B., de Sá L.C., Valacio R.A., Ziegelmann P.K. Systematic review and meta-analysis of ivermectin for treatment of COVID-19: Evidence beyond the hype. BMC Infect. Dis. 2022;22:639. doi: 10.1186/s12879-022-07589-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07589-8</ArticleId><ArticleId IdType="pmc">PMC9308124</ArticleId><ArticleId IdType="pubmed">35870876</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz I.S., Boulware D.R., Lee T.C. Hydroxychloroquine for COVID19: The curtains close on a comedy of errors. Lancet Reg. Health Am. 2022;11:100268. doi: 10.1016/j.lana.2022.100268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100268</ArticleId><ArticleId IdType="pmc">PMC9069223</ArticleId><ArticleId IdType="pubmed">35531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla A.K., Misra S. The Use of Ivermectin in the Treatment of COVID-19. J. Gen. Intern. Med. 2023;38:1554. doi: 10.1007/s11606-023-08104-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-023-08104-8</ArticleId><ArticleId IdType="pmc">PMC9974046</ArticleId><ArticleId IdType="pubmed">36854869</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Approves First Treatment for COVID-19 FDA.  [(accessed on 1 September 2024)];2020  Available online:  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.</Citation></Reference><Reference><Citation>Cihlar T., Mackman R.L. Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antivir. Ther. 2022;27:13596535221082773. doi: 10.1177/13596535221082773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13596535221082773</ArticleId><ArticleId IdType="pubmed">35499114</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver S.E., Gargano J.W., Marin M., Wallace M., Curran K.G., Chamberland M., McClung N., Campos-Outcalt D., Morgan R.L., Mbaeyi S., et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine—United States, December 2020. MMWR. Morb. Mortal. Wkly. Rep. 2020;69:1922–1924. doi: 10.15585/mmwr.mm6950e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6950e2</ArticleId><ArticleId IdType="pmc">PMC7745957</ArticleId><ArticleId IdType="pubmed">33332292</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver S.E., Gargano W., Marin M., Wallace M., Curran K.G., Chamberland M., McClung N., Campos-Outcalt D., Morgan L., Mbaeyi S., et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine—United States, December 2020. MMWR. Morb. Mortal. Wkly. Rep. 2021;69:1653–1656. doi: 10.15585/mmwr.mm695152e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm695152e1</ArticleId><ArticleId IdType="pmc">PMC9191904</ArticleId><ArticleId IdType="pubmed">33382675</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson J. FDA Authorizes Pharmacists to Prescribe Oral Antiviral Medication for COVID-19. JAMA Health Forum. 2022;3:e222968. doi: 10.1001/jamahealthforum.2022.2968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2022.2968</ArticleId><ArticleId IdType="pubmed">36219005</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults.  [(accessed on 1 September 2024)];2021  Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain.</Citation></Reference><Reference><Citation>O’Keefe B.R., Beutler J.A., Cardellina J.H., Gulakowski R.J., Krepps B.L., Mcmahon J.B., Sowder R.C., II, Henderson L.E., Pannell L.K., Pomponi S.A., et al. Isolation and characterization of niphatevirin, a human-immunodeficiency-virus-inhibitory glycoprotein from the marine sponge Niphates erecta. Eur. J. Biochem. 1997;245:47–53. doi: 10.1111/j.1432-1033.1997.t01-1-00047.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-1033.1997.t01-1-00047.x</ArticleId><ArticleId IdType="pubmed">9128723</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Pradhan M., Gorshkov K., Petersen J.D., Shen M., Guo H., Zhu W., Klumpp-Thomas C., Michael S., Itkin M., et al. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. SLAS Discov. 2022;27:86–94. doi: 10.1016/j.slasd.2021.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.slasd.2021.12.005</ArticleId><ArticleId IdType="pmc">PMC8720380</ArticleId><ArticleId IdType="pubmed">35086793</ArticleId></ArticleIdList></Reference><Reference><Citation>Muñoz-Basagoiti J., Monteiro F.L.L., Krumpe L.R., Armario-Najera V., Shenoy S.R., Perez-Zsolt D., Westgarth H.J., Villorbina G., Bomfim L.M., Raïch-Regué D., et al. Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 2023;120:e2214561120. doi: 10.1073/pnas.2214561120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2214561120</ArticleId><ArticleId IdType="pmc">PMC10013841</ArticleId><ArticleId IdType="pubmed">36853940</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano J., Puupponen-Pimiä R., Dauer A., Aura A.M., Saura-Calixto F. Tannins: Current knowledge of food sources, intake, bioavailability and biological effects. Mol. Nutr. Food Res. 2009;53:S310–S329. doi: 10.1002/mnfr.200900039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.200900039</ArticleId><ArticleId IdType="pubmed">19437486</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima H., Murakami T., Yamamoto N., Sakagami H., Tanuma S.I., Hatano T., Yoshida T., Okuda T. Inhibition of human immunodeficiency viral replication by tannins and related compounds. Antiviral Res. 1992;18:91–103. doi: 10.1016/0166-3542(92)90008-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(92)90008-S</ArticleId><ArticleId IdType="pubmed">1416904</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestle D., Heindl M.R., Limburg H., Pilgram O., Moulton H., Stein D.A., Stein D.A., Hardes K., Eickmann M., Dolnik O., et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance. 2020;3:e202000786. doi: 10.26508/lsa.202000786.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202000786</ArticleId><ArticleId IdType="pmc">PMC7383062</ArticleId><ArticleId IdType="pubmed">32703818</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369:330–333. doi: 10.1126/science.abb9983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb9983</ArticleId><ArticleId IdType="pmc">PMC7199903</ArticleId><ArticleId IdType="pubmed">32366695</ArticleId></ArticleIdList></Reference><Reference><Citation>Garten W. Characterization of Proprotein Convertases and Their Involvement in Virus Propagation. Act. Viruses Host Proteases. 2018:205–248. doi: 10.1007/978-3-319-75474-1_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-75474-1_9</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>